This is an open-label, multicenter study designed to evaluate the efficacy and safety of reducing oral corticosteroid (OCS) use after initiation of a 30 mg dose of benralizumab administered subcutaneously (SC) every 4 weeks (Q4W) up until the third dose of benralizumab and then every 8 weeks (Q8W) thereafter in patients with severe eosinophilic asthma who are receiving high-dose inhaled corticosteroids (ICS)/long-acting β2 agonists (LABAs) and OCS with or without additional asthma controller(s). After they sign the informed consent form, patients will undergo a screening visit (Visit 1) to assess eligibility criteria and laboratory tests. All patients who are not already taking prednisone/prednisolone as their OCS treatment will be switched to prednisone/prednisolone, and the laboratory tests will be delayed 3 to 7 days. Patients still fulfilling inclusion/ sion criteria at Visit 2 (Week 0) will enter the study and receive open-label benralizumab.More
Male and female patients aged ≥18 years with diagnosed asthma and requiring continuous treatment with high-dose ICS (high-dose ICS at the highest approved dose in a country) plus LABAs for ≥6 months. Patients must be on chronic treatment with OCS (equivalent to a prednisone dose of ≥5 mg/day) for ≥3 months prior to study entry. The OCS dose must be stable for ≥4 weeks prior to study entry. Patients must have peripheral blood eosinophil counts of ≥150 cells/μL as assessed by a central laboratory documented eosinophil count of ≥300 cells/μL in the past 12 months.
1. Known history of allergy or reaction to the study drug formulation 2. History of alcohol abuse within 12 months prior to the date informed consent is obtained 3. Received previous treatment with benralizumab in the present study 4.
University of Colorado Hospital
Fernando Holguin, MD
Protocol Number: 18-1978
More information available at ClinicalTrials.gov: NCT03557307
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers